Effect of cocaine use on methadone pharmacokinetics in humans

American Journal on Addictions

Volumn 19, Issue 1, 2010, Pages 47-52

  McCance Katz, Elinore F ^a,d   Jatlow, Peter ^b   Rainey, Petrie M ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE;

ADULT; ADVERSE OUTCOME; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; FEMALE; HUMAN; MALE; OPIATE ADDICTION; PHARMACOKINETICS; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; COCAINE; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; METHADONE;

EID: 77149177066     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2009.00009.x     Document Type: Article

References (37)

1. Leri F, Bruneau J, Stewart J. Understanding polydrug use: Review of heroin and cocaine co-use. Addiction. 2003 98 : 7 22.
2. Grella CE, Anglin MD, Wugalter SE. Patterns and predictors of cocaine and crack use by clients in standard and enhanced methadone maintenance treatment. Am J Drug Alcohol Abuse. 1997 23 : 15 42.
3. Neufeld K, King V, Peirce J, et al. A comparison of 1-year substance abuse treatment outcomes in community syringe exchange participants versus other referrals. Drug Alcohol Depend. 2008 97 : 122 129.
4. Kamal F, Flavin S, Campbell F, et al. Factors affecting the outcome of methadone maintenance treatment in opiate dependence. Ir Med J. 2007 100 : 393 397.
5. Maremmani I, Pani PP, Mellini A, et al. Alcohol and cocaine use and abuse among opioid addicts engaged in a methadone maintenance treatment program. J Addict Dis. 2007 26 : 61 70.
6. McCance-Katz EF, Rainey PM, Moody DE. Effect of cocaine use on buprenorphine pharmacokinetics in humans. Am J Addict. DOI : 10.1111/j.1521-0391.2009.00001.x.
7. McCance-Katz EF, Rainey P, Smith P, et al. Drug interactions between opioid and antiretroviral medications: Interaction between methadone, LAAM, and nelfinavir. Am J Addict. 2004 13 : 163 180.
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn. Washington, DC : American Psychiatric Association 1994.
9. Chang Y, Moody DE, McCance-Katz EF. Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metab Dispos. 2006 34 : 440 448.
10. Picard N, Cresteil T, Djebli N, et al. In vitro metabolism study of buprenorphine: Evidence for new metabolic pathways. Drug Metab Dispos. 2005 33 : 689 695.
11. Zhang W, Ramamoorthy Y, Tyndale RF, et al. Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003 31 : 768 772.
12. Kobayashi K, Yamamoto T, Chiba K, et al. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos. 1998 26 : 818 821.
13. Iribarne C, Picart D, Dréano Y, et al. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci. 1997 60 : 1953 1964.
14. Iribarne C, Berthou F, Baird S, et al. Involvement of cytochrome P450 3A4 enzyme in the n-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 9 : 365 373.
15. Totah RA, Sheffels P, Roberts T, et al. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology. 2008 108 : 363 374.
16. Baselt RC, Casarett LJ. Urinary excretion of methadone in man. Clin Pharm Ther. 1972 13 : 64 70.
17. Maurer HH, Sauer C, Theobald DS. Toxicokinetics of drugs of abuse: Current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and codeine. Ther Drug Monit. 2006 28 : 447 453.
18. Laizure SC, Mandrell T, Gades NM, et al. Cocaethylene metabolism and interaction with cocaine and ethanol: Role of carboxylesterases. Drug Metab Dispos. 2003 31 : 16 20.
19. Brzezinski MR, Spink BJ, Dean RA, et al. Human liver carboxylesterase hCE-1: Binding specificity for cocaine, heroin, and their metabolites and analogs. Drug Metab Dispos. 1997 25 : 1089 1096.
20. Dean RA, Christian CD, Sample RH, et al. Human liver cocaine esterases: Ethanol-mediated formation of ethylcocaine. FASEB J. 1991 5 : 2735 2739.
21. Zhu HJ, Appel DI, Johnson JA, et al. Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril. Biochem Pharmacol. 2009 77 : 1266 1272.
22. Kloss MW, Rosen GM, Rauckman EJ. N-demethylation of cocaine to norcocaine. Evidence for participation by cytochrome P-450 and FAD-containing monooxygenase. Mol Pharmacol. 1983 23 : 482 485.
23. LeDuc BW, Sinclair PR, Shuster L, et al. Norcocaine and N-hydroxynorcocaine formation in human liver microsomes: Role of cytochrome P-450 3A4. Pharmacology. 1993 46 : 294 300.
24. Pellinen P, Kulmala L, Konttila J, et al. Kinetic characteristics of norcocaine N-hydroxylation in mouse and human liver microsomes: Involvement of CYP enzymes. Arch Toxicol. 2000 74 : 511 520.
25. Brogan WC, Lange RA, Glamann DB, et al. Recurrent coronary vasoconstriction caused by intranasal cocaine: Possible role for metabolites. Ann Intern Med. 1992 116 : 556 561.
26. Lopez P, Velez R, Rivera V. Characteristics of P-glycoprotein (Pgp) upregulated in chronic cocaine users and HIV infected persons. Retrovirology. 2005 2 (Suppl 1 142.
27. Pellinen P, Stenbäck F, Kojo A, et al. Regenerative changes in hepatic morphology and enhanced expression of CYP2B10 and CYP3A during daily administration of cocaine. Hepatology. 1996 23 : 515 523.
28. Kharasch ED, Hoffer C, Whittington D, et al. Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: Insights from methadone interactions with ritonavir/indinavir. Anesthesiology. 2009 110 : 660 672.
29. Ferrari A, Coccia CP, Bertolini A, et al. Methadone-metabolism, pharmacokinetics and interactions. Pharmacol Res. 2004 50 : 551 559.
30. McCance-Katz EF, Rainey P, Friedland G, et al. The protease inhibitor lopinavir/ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis. 2003 37 : 476 482.
31. McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. Am J Addict. DOI : 10.1111/j.1521-0391.2009. 00005.x.
32. Neufeld K, King V, Peirce J, et al. A comparison of 1-year substance abuse treatment outcomes in community syringe exchange participants versus other referrals. Drug Alcohol Depend. 2008 97 : 122 129.
33. Kamal F, Flavin S, Campbell F, et al. Factors affecting the outcome of methadone maintenance treatment in opiate dependence. Ir Med J. 2007 100 : 393 397.
34. Maremmani I, Pani PP, Mellini A, et al. Alcohol and cocaine use and abuse among opioid addicts engaged in a methadone maintenance treatment program. J Addict Dis. 2007 26 : 61 70.
35. Kratz JM, Martin J, Stimmel B, et al. QTc interval screening in methadone treatment. Ann Intern Med. 2009 150 : 387 395.
36. Krantz MJ, Kutinsky IB, Robertson AD, et al. Dose-related effects of methadone on QT prolongation in a series of patients with Torsades de Pointes. Pharmacotherapy. 2003 23 : 802 805.
37. Phillips K, Luk A, Soor GS, et al. Cocaine cardiotoxicity: a review of the pathophysiology, pathology, and treatment options. Am J Cardiovasc Drugs. 2009 9 : 177 196.